

---

# Wisconsin Legislative Council

## ACT MEMO

---



**Prepared by:** Steve McCarthy, Staff Attorney

April 3, 2020

**2019 Wisconsin Act 150**  
[2019 Senate Bill 489]

**Clinical Cancer Trial  
Reimbursement**

### **2019 WISCONSIN ACT 150**

The act provides that reimbursement of certain patient-incurred expenses, including travel and ancillary costs related to participation in a cancer clinical trial, is not considered undue inducement to participate in a cancer clinical trial.

The act requires all sponsors of cancer clinical trials to provide potential participants, during the informed consent process, with information relating to the possible availability of reimbursement for certain expenses. Under the act, language informing patient-subjects that reimbursement entities or programs that cover travel, ancillary costs, and other direct patient-incurred expenses may be available must be submitted for review to the relevant federally designated institutional review board in conjunction with the review of a proposed cancer clinical trial and included in the informed consent form approved by the institutional review board. The reimbursement entity or program must also disclose the nature of the ancillary support and general guidelines on financial eligibility to interested patient-subjects and employ a reimbursement process that conforms to federal law and guidance.

**Effective date:** March 5, 2020

SM:mca;ty